MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40262-025-01539-8

Медицинская библиотека · Clinical pharmacokinetics · 2025

SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study.

Qin Ruzhai, Ye Lika, Duan Lian, Li Mingyan, He Wenkai, Mei Xiao, Li Deen, Jin Rong, Lv Chao, Zhu Min, Wang Shihui, Xie Zhihong

СтатьяРандомизированное исследованиеКлиническое исследование I фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

Angiopoietin-like 3 (ANGPTL3) increases serum low-density lipoprotein cholesterol and triglyceride by reducing their clearance. SHR-1918 is a monoclonal antibody against ANGPTL3. This study assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SHR-1918 in healthy subjects.

METHODS

Six dose cohorts (100, 300, 450, 750, 900, and 1200 mg) were planned, each containing 12 healthy subjects randomized (9:3) to receive a single dose of subcutaneous SHR-1918 or placebo. Subjects were followed up to day 148 for the 100-mg cohort and day 190 for the other cohorts.

RESULTS

A total of 72 subjects were enrolled (SHR-1918, n = 54; placebo, n = 18). SHR-1918 was well tolerated at 100-1200 mg. Treatment-emergent adverse events were comparable between the SHR-1918 (90.7%) and placebo (94.4%) groups. All treatment-emergent adverse events were mild or moderate in severity, with no serious adverse events or treatment-emergent adverse events leading to death. Maximum serum concentration was reached 7.98-10.0 days after injection, and mean half-life was 29.4-53.5 days across the dose range. Serum low-density lipoprotein cholesterol and triglyceride markedly and rapidly decreased upon SHR-1918 administration, whereas those in the placebo group were above baseline at most follow-up visits. The largest median percentage decline in serum low-density lipoprotein cholesterol and triglyceride ranged from - 28.7 to - 49.1% and from - 46.6 to - 82.8%, respectively. For dose levels 300 mg or higher, the low-density lipoprotein cholesterol reduction remained over 30% for 64 days and triglyceride reduction remained over 50% for 85 days.

CONCLUSIONS

SHR-1918 was well tolerated and showed promising efficacy in lipid reduction among healthy subjects.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT05432544 (24 June, 2022).

Для цитирования: Qin Ruzhai, Ye Lika, Duan Lian, Li Mingyan, He Wenkai, Mei Xiao, Li Deen, Jin Rong, Lv Chao, Zhu Min, Wang Shihui, Xie Zhihong. SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study.. Clinical pharmacokinetics. 2025. DOI: 10.1007/s40262-025-01539-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.